TITLE: KubS-Hera (RPRDiB) Deficiency as a Clinically Relevant Biomarker of PARP Inhibitor Sensitivity in BRCA-Proficient Cancers.

INVENTORS: David Boothman, Edward Motea, Praveen Patidar, Julio Morales

TECHNOLOGY: Diagnostics

UTSD: 2814

SUMMARY: Kub5-Hera can regulate resistance to cancer treatments by its ability to modulate the stability and expression of crucial factors involved in cell cycle control, DNA damage response, and DNA repair. This invention relates to a method of determining the suitable treatment of cancer in a subject by measuring copy number variation, mRNA and/or protein expression level of Kub5-Hera.

Please contact the Office for Technology Development for more details:

Phone: 214-648-1888

Email: TechnologyDevelopment@utsouthwestern.edu

Please reference UT Southwestern Case Number: 2814